Cleave Therapeutics, Inc.

Cleave Therapeutics is a biopharmaceutical company founded in 2010, headquartered in the United States, with a focus on developing VCP/p97 inhibitors for oncology and neurodegenerative diseases. The company's lead drug development candidate, CB-5339, is a potent, oral, selective, second-generation inhibitor of VCP/p97, which addresses the limitations of earlier compounds, including exposure and selectivity to the target. Cleave Therapeutics has garnered significant attention, receiving a $12.00M Series C investment in August 2019 from a distinguished group of investors including US Venture Partners, 5AM Ventures, OrbiMed, Osage University Partners, Arcus Ventures, Astellas Venture Management, and Celgene. The company is collaborating with the National Cancer Institute (NCI) and leading academic institutions to advance VCP/p97 inhibitors for cancer and neurodegenerative diseases. Cleave's oncology drug discovery pipeline is designed to target cancer stress pathways, leveraging the crucial role of VCP/p97 in protein homeostasis and cellular stress critical for cancer cell growth and survival. In the field of neurodegenerative diseases, Cleave’s research has shown the potential for therapeutic benefit, particularly in addressing the health and function of mitochondria for patients with limited treatment options. This innovative approach has the potential to address significant unmet medical needs. With a strong focus on VCP/p97 as a critical target in protein homeostasis and stress pathways, Cleave Therapeutics is poised to make impactful advancements in the treatment of cancer and neurodegenerative diseases.